Clinical outcomes of apixaban in patients with atrial fibrillation and very high thromboembolic risk (CHA₂DS₂-VASc ≥5): a retrospective cohort study

Abstract Background Real-world evidence on apixaban in patients with atrial fibrillation (AF) at very high thromboembolic risk (CHA₂DS₂-VASc ≥ 5) is limited, particularly from the Middle East. We compared clinical outcomes between apixaban-treated patients with CHA₂DS₂-VASc scores ≥ 5 and 0–4, and between prescribed doses within the very high-risk group. Methods In this retrospective cohort study at a tertiary referral center in Makkah, Saudi Arabia, adults with AF treated with apixaban between January 2019 and December 2024 were grouped by baseline CHA₂DS₂-VASc score. Outcomes were documented thromboembolic events, bleeding of any severity, and in-hospital mortality. Odds ratios (ORs) were estimated by unadjusted and multivariable logistic regression. A sensitivity analysis excluded patients with a recorded prior stroke. Results Of 596 patients, 175 (29.4%) had scores ≥ 5. Thromboembolic events (31.4% vs 7.1%; adjusted OR 6.6, 95% CI 3.9–11.0) and in-hospital mortality (14.3% vs 1.7%; adjusted OR 7.7, 95% CI 3.2–18.5) were more frequent with scores ≥ 5, whereas bleeding did not differ significantly (54.9% vs 46.8%; adjusted OR 1.3, 95% CI 0.9–1.9). Of 68 patients with a recorded prior stroke, 58 also had a documented thromboembolic event; after their exclusion, thromboembolic events no longer differed (5.2% vs 5.1%), whereas bleeding (adjusted OR 3.2, 95% CI 2.0–5.1) and mortality (adjusted OR 8.7, 95% CI 3.4–22.1) were more frequent with scores ≥ 5. Among very high-risk patients, prescribed dose (2.5 mg, n = 73; 5 mg, n = 102, twice daily) was not significantly associated with any outcome. Conclusions A CHA₂DS₂-VASc score ≥ 5 was associated with higher in-hospital mortality among apixaban-treated patients with AF. The excess of thromboembolic events was confined to patients with a recorded prior stroke and may reflect overlap between baseline history and outcome recording. Prescribed dose was not associated with outcomes, although dose appropriateness could not be assessed. Larger studies with complete dosing criteria and event timing are needed.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-17
DOI
https://doi.org/10.21203/rs.3.rs-11747302/v1
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clinical outcomes of apixaban in patients with atrial fibrillation and very high thromboembolic risk (CHA₂DS₂-VASc ≥5): a retrospective cohort study

Abrar F. Alshehri, Mohammed A. Alnuhait, Asma M. Alshahrani, Mohammed Abdulrahman Alrashed et al.
2 links
Research Square
Atrial Fibrillation Management and Outcomes
preprint

Clinical outcomes of apixaban in patients with atrial fibrillation and very high thromboembolic risk (CHA₂DS₂-VASc ≥5): a retrospective cohort study

Abrar F. Alshehri, Mohammed A. Alnuhait, Asma M. Alshahrani, Mohammed Abdulrahman Alrashed, Shaimaa Alsulami, Abdullah S. Alshammari, Saud A. Hijazi, Qussi H. Basranah, Fatimah M. Hamdi, Saleh Alghamdi, Emad Elkholy, Tamim N. Alkhaldi
preprint en

Abstract

Abstract Background Real-world evidence on apixaban in patients with atrial fibrillation (AF) at very high thromboembolic risk (CHA₂DS₂-VASc ≥ 5) is limited, particularly from the Middle East. We compared clinical outcomes between apixaban-treated patients with CHA₂DS₂-VASc scores ≥ 5 and 0–4, and between prescribed doses within the very high-risk group. Methods In this retrospective cohort study at a tertiary referral center in Makkah, Saudi Arabia, adults with AF treated with apixaban between January 2019 and December 2024 were grouped by baseline CHA₂DS₂-VASc score. Outcomes were documented thromboembolic events, bleeding of any severity, and in-hospital mortality. Odds ratios (ORs) were estimated by unadjusted and multivariable logistic regression. A sensitivity analysis excluded patients with a recorded prior stroke. Results Of 596 patients, 175 (29.4%) had scores ≥ 5. Thromboembolic events (31.4% vs 7.1%; adjusted OR 6.6, 95% CI 3.9–11.0) and in-hospital mortality (14.3% vs 1.7%; adjusted OR 7.7, 95% CI 3.2–18.5) were more frequent with scores ≥ 5, whereas bleeding did not differ significantly (54.9% vs 46.8%; adjusted OR 1.3, 95% CI 0.9–1.9). Of 68 patients with a recorded prior stroke, 58 also had a documented thromboembolic event; after their exclusion, thromboembolic events no longer differed (5.2% vs 5.1%), whereas bleeding (adjusted OR 3.2, 95% CI 2.0–5.1) and mortality (adjusted OR 8.7, 95% CI 3.4–22.1) were more frequent with scores ≥ 5. Among very high-risk patients, prescribed dose (2.5 mg, n = 73; 5 mg, n = 102, twice daily) was not significantly associated with any outcome. Conclusions A CHA₂DS₂-VASc score ≥ 5 was associated with higher in-hospital mortality among apixaban-treated patients with AF. The excess of thromboembolic events was confined to patients with a recorded prior stroke and may reflect overlap between baseline history and outcome recording. Prescribed dose was not associated with outcomes, although dose appropriateness could not be assessed. Larger studies with complete dosing criteria and event timing are needed.

Research Square
King Saud bin Abdulaziz University for Health Sciences (SA), Umm al-Qura University (SA), Shaqra University (SA), King Abdullah Medical City (SA), Al Baha University (SA)
Good health and well-being
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon